Envista Holdings Corp
Envista (NYSE: NVST) develops, manufactures and markets dental products, technologies and services for dental professionals and patients. Its portfolio includes dental implants and prosthetics, orthodontic brackets and clear aligners, digital imaging and scanning systems, treatment-planning software, restorative and… From the company’s description.
In fiscal 2025, Envista Holdings Corp reported revenue of $2.72B, up 8.3% from fiscal 2024, and net income of $47.00M. Its operating margin was 7.9%, and operations generated $275.70M in cash. Over the twelve months to Jul 3, 2026, revenue was $2.86B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Envista Holdings Corp does
In the company’s own words
Envista (NYSE: NVST) develops, manufactures and markets dental products, technologies and services for dental professionals and patients. Its portfolio includes dental implants and prosthetics, orthodontic brackets and clear aligners, digital imaging and scanning systems, treatment-planning software, restorative and endodontic products, infection-prevention supplies and dental equipment. Customers include general dentists, orthodontists, oral surgeons, dental laboratories, dental service organizations and distributors. The company operates through Specialty Products & Technologies, covering dental implants and orthodontics, and Equipment & Consumables, covering diagnostic and consumables solutions; these segments accounted for 64% and 36% of 2025 sales, respectively. Envista serves professionals in more than 130 countries and generated $2.7 billion in sales in 2025. Its brands include Nobel Biocare, Ormco, Spark, DEXIS, Kerr and Metrex. Formed as a Danaher subsidiary in 2018, Envista became an independent public company in 2019. Its website is www.envistaco.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Medical Instruments
- Headquarters
- BREA, CA
- Fiscal year end
- December
- CIK
- 1757073
- SIC
- 3843
Financial performance, year by year
Fiscal 2019–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Envista Holdings Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Envista Holdings Corp · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Envista Holdings Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Envista Holdings Corp’s bonds, as funds hold them
Funds report holding 1 issues of Envista Holdings Corp’s debt, $116.56M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 1.75%, maturing 2028 to 2028.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Envista Holdings Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Envista Holdings Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Envista Holdings Corp's last four quarterly filings that the numbers alone won't show?”